Biomarkers, Diagnostics and Precision Medicine in the Drug Industry Critical Challenges, Limitations and Roadmaps for the Best Practices
Auteur : Halim Abdel
The high failure rate in the pharmaceutical industry has positioned biomarkers and personalized medicine in the frontline, as possible solutions. If executed right, biomarkers and companion diagnostics (CDx) can potentially help the drug industry enhance the probability of success, accelerate the time to market, and, more importantly, benefit patients by supporting accurate diagnosis and selection of the most effective and least toxic therapies. This book aims to examine the challenges and limitations in biomarkers and laboratory tests. It also offers advice on best practices to ensure proper application of biomarkers and bridges the gap between diagnostic business development claims and real-life deliverables. The book covers biomarkers for different purposes, provides examples from different technologies, which includes standard-of-care approved assays as well as for-investigational-use and for-research-use-only assays. It also includes new data for biomarkers in different therapeutic indications and offers case studies and practical examples.
This book serves as a reference to drug developers, IVD providers, clinical labs, healthcare givers, academicians, and researchers for best practices to help increase the probability of success in drug development and improve patient management.
1. Pharmaceutical crisis2. Applications of biomarkers for different purposes in drug development 3. Pharmacogenetics of therapeutics4. Precision medicine and companion diagnostics in drug development5. Essential attributes of an acceptable in-vitro diagnostic test6. Fundamentals of Assay Development and Validation7. Essentials of Laboratory Quality Management8. Biological variables and their potential impact on biomarkers and precision medicine initiative9. Pre-analytical Variables and their potential impact on biomarkers and precision medicine initiative10. Analytical Discrepancies and their potential impact on biomarkers and precision medicine initiative11. Road Map to Best Practices
Drug developers (from startup biotech to well-established global companies) from early discovery to registrational phases, clinicians managing patients or clinical trials, clinical researchers, clinical laboratories, diagnostic companies, and regulatory agencies.
Before Taiho, Dr. Halim held multiple leadership positions in the pharmaceutical and diagnostic industries. He oversaw the development and validation of assays for several hundreds of biomarkers on different platforms and their applications in 150+ PI-PIII clinical trials and patient managements. Abdel has led 8 CDx programs and has track records for 5 FDA high complexity IVD approvals and 2 drug approvals. Abdel has served on 20+ governmental and public expert panels and advisory boards in the US, Canada and EU. Dr. Halim has served on 25+ committees to establish guidelines to promote quality in clinical laboratory and diagnostic industries and authored about 15 guidelines. Abdel has 70+ peer-reviewed publications, two book chapters and 100+ presentations including 40+ invited and keynote speeches in national and international meetings.
- Provides the unique insight of an expert with extensive experience in diagnostics and clinical laboratory on one side and drug discovery and development on the other side
- Addresses the challenges of drug development and precision medicine and suggests how to eliminate or mitigate these challenges through better utilization of biomarkers and diagnostics in drug development and patient management
- Features case studies and real-life examples from different classes of biomarkers on different platforms for different therapeutic areas and includes more than 200 illustrations
Date de parution : 06-2019
Ouvrage de 294 p.
21.4x27.6 cm
